Back to News
Market Impact: 0.2
B. Riley Securities Initiates Coverage of Neuronetics at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
B. Riley Securities initiated coverage of Neuronetics (NASDAQGM: STIM) on September 11, 2026, with a Buy recommendation. The initiation is a positive analyst endorsement for the U.S. medical-device company, though the article provides no price target, earnings estimates, or additional investment rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
STIM0.55
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Buy Tesla ahead of potential SpaceX merger, says Barclays
- JPMorgan’s Michele Sees US Bonds Returning 7%-8% Over 12 Months
- +52%, +39%, +22%: Our AI just called these blue-chip breakouts
- As AI becomes more fractured, one names stands out: AMD
- Carnage beneath the record high: How to find cheap stocks without the traps